MINNEAPOLIS, Oct. 19 /PRNewswire-FirstCall/ -- Vascular Solutions, Inc. today announced the schedule of significant scientific presentations to occur at the annual Transcatheter Cardiovascular Therapeutics (TCT) 18th Annual Scientific Symposium October 22 - 27 at the Washington Convention Center in Washington, D.C. concerning Vascular Solutions' products.
Dr. Robert J. Applegate of Wake Forest University School of Medicine will present a single-center observational study on the use of the D-Stat Dry in 3,464 consecutive unselected patients: 2,464 patients undergoing diagnostic cardiac catheterizations and 1,000 patients undergoing percutaneous coronary intervention procedures. Dr. Applegate's presentation will be included in the downloadable electronic poster session of the TCT meeting.
Dr. Jacopo A. Oreglia of Niguarda Hospital in Milan, Italy will make two separate presentations involving the Pronto extraction catheter on Tuesday, October 24:
-- "Impact of Thrombus Aspiration in Acute Myocardial Infarction on Procedural Aspects of Primary Percutaneous Intervention" at 8:30 a.m. ET at the "Protection and Thrombectomy Devices in the Coronary and Peripheral Circulations" session in Room 152AB. -- "Positive Results With the Simplicity of Thromboaspiration: Angiographic and Extended Clinical Results From DEAR-MI and Other Studies" at 1:59 p.m. ET at the "Thrombectomy and Distal Protection in AMI: A Rational Concept Waiting for Proof" session in Room 207AM. About Vascular Solutions
Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within Interventional radiology and Interventional cardiology. New products introduced since the second half of 2003 include the Vari-Lase(R) endovenous laser product line for the treatment of varicose veins, the D-Stat Dry(TM) hemostatic bandage for the rapid control of topical bleeding, the Pronto(TM) extraction catheter for the aspiration of soft thrombus, the Langston(R) dual lumen catheter for the measurement of aortic stenosis and the Twin-Pass(TM) dual access catheter for dual wire access in interventional procedures. The Company's other major products include the Duett(TM) sealing device to rapidly seal the puncture site following catheterization procedures and the D-Stat(R) Flowable hemostat for the local management of active bleeding.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2005 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of profitability, exposure to intellectual property claims, dependence on key vendors, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to http://www.vascularsolutions.com .
Vascular Solutions, Inc.CONTACT: Howard Root, CEO, or James Hennen, CFO, both of VascularSolutions, Inc., +1-763-656-4300
Web site: http://www.vascularsolutions.com/
